Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
Public ClinicalTrials.gov record NCT01693068. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Study identification
- NCT ID
- NCT01693068
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- EMD Serono
- Industry
- Enrollment
- 194 participants
Conditions and interventions
Interventions
- Pimasertib Drug
- Dacarbazine Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 4, 2012
- Primary completion
- Jul 3, 2015
- Completion
- Oct 23, 2016
- Last update posted
- Jan 4, 2018
2012 – 2016
United States locations
- U.S. sites
- 15
- U.S. states
- 13
- U.S. cities
- 15
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Research Site | Birmingham | Alabama | — | — |
| Research Site | Tucson | Arizona | — | — |
| Research Site | San Francisco | California | — | — |
| Research Site | Miami Beach | Florida | — | — |
| Research Site | Orlando | Florida | — | — |
| Research Site | Maywood | Illinois | — | — |
| Research Site | Indianapolis | Indiana | — | — |
| Research Site | Boston | Massachusetts | — | — |
| Please contact the US Medical Information in | Rockland | Massachusetts | — | — |
| Research Site | St Louis | Missouri | — | — |
| Research Site | Morristown | New Jersey | — | — |
| Research Site | New York | New York | — | — |
| Research Site | Columbus | Ohio | — | — |
| Research Site | Dallas | Texas | — | — |
| Research Site | Madison | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 86 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01693068, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 4, 2018 · Synced Jul 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01693068 live on ClinicalTrials.gov.